A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Seviprotimut-L (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms MAVIS
- Sponsors Polynoma
- 03 Apr 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Apr 2018.
- 28 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.